Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 1,400 shares, a decline of 22.2% from the September 30th total of 1,800 shares. Based on an average daily trading volume, of 21,200 shares, the short-interest ratio is presently 0.1 days.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. Berenberg Bank upgraded shares of Novozymes A/S to a "strong-buy" rating in a research report on Tuesday, September 24th. Citigroup downgraded shares of Novozymes A/S from a "neutral" rating to a "sell" rating in a report on Thursday, October 17th.
Read Our Latest Report on Novozymes A/S
Novozymes A/S Trading Down 0.7 %
NVZMY traded down $0.42 on Friday, hitting $63.79. The company had a trading volume of 6,190 shares, compared to its average volume of 12,530. The company's fifty day moving average price is $68.22 and its 200 day moving average price is $63.25. Novozymes A/S has a 1 year low of $41.35 and a 1 year high of $72.50. The firm has a market cap of $29.87 billion, a P/E ratio of 40.37, a PEG ratio of 3.87 and a beta of 0.89.
Novozymes A/S Cuts Dividend
The company also recently declared a dividend, which was paid on Wednesday, September 18th. Stockholders of record on Monday, September 9th were given a dividend of $0.1678 per share. The ex-dividend date of this dividend was Monday, September 9th. Novozymes A/S's dividend payout ratio is currently 41.77%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Featured Stories
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.